AngioDynamics

ANGO · NASDAQ

$11.81−$0.11 (−0.92%)TodayMarket closed · Oct 21, 4:08 AM ET

Prev close $11.92

Latest news

Press releaseOct 14, 7:00 AM ETBusiness Wire
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
NewsOct 8, 1:44 PM ETVandana Singh
AngioDynamics Stock Is Falling Thursday: What's Going On?
NewsOct 8, 12:03 PM ETAvi Kapoor
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
NewsOct 8, 9:11 AM ET
AngioDynamics Q1 2027 Earnings Call: Complete Transcript
NewsOct 8, 7:11 AM ET
Earnings Scheduled For October 8, 2026
Press releaseOct 8, 6:02 AM ETBusiness Wire
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
Press releaseOct 8, 6:00 AM ETBusiness Wire
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
Press releaseOct 2, 6:00 AM ETBusiness Wire
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
Press releaseSep 28, 4:30 PM ETBusiness Wire
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
NewsAug 12, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseJul 28, 8:30 AM ETBusiness Wire
AngioDynamics to Participate in Upcoming Investor Conferences
NewsJul 14, 9:02 AM ET
Full Transcript: AngioDynamics Q4 2026 Earnings Call
NewsJul 14, 7:11 AM ET
Earnings Scheduled For July 14, 2026
Press releaseJul 14, 6:00 AM ETBusiness Wire
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
Press releaseJun 30, 8:00 AM ETBusiness Wire
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
Press releaseJun 17, 8:30 AM ETBusiness Wire
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
Press releaseMay 28, 1:25 PM ETBusiness Wire
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
Press releaseMay 27, 8:30 AM ETBusiness Wire
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Press releaseMay 13, 9:00 AM ETBusiness Wire
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
NewsApr 2, 7:11 AM ET
Earnings Scheduled For April 2, 2026
Press releaseApr 2, 6:00 AM ETBusiness Wire
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
Press releaseMar 31, 8:00 AM ETBusiness Wire
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
Press releaseMar 19, 8:00 AM ETBusiness Wire
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026
Press releaseFeb 23, 4:30 PM ETBusiness Wire
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
Press releaseFeb 19, 8:30 AM ETBusiness Wire
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
Press releaseFeb 5, 8:00 AM ETBusiness Wire
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
Press releaseFeb 3, 8:00 AM ETBusiness Wire
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
NewsJan 6, 12:58 PM ETAvi Kapoor
Dow Jumps Over 400 Points; US Services Activity Falls In December
NewsJan 6, 9:49 AM ETAvi Kapoor
US Stocks Mixed; Nasdaq Gains Over 50 Points
Press releaseJan 6, 6:00 AM ETBusiness Wire
AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
NewsJan 5, 9:00 AM ET
What to Expect from AngioDynamics's Earnings
NewsDec 30, 6:51 AM ETAvi Kapoor
AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Press releaseDec 23, 8:00 AM ETBusiness Wire
AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026
Press releaseDec 22, 8:00 AM ETBusiness Wire
AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

AngioDynamics Stock Is Falling Thursday: What's Going On?

Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings

AngioDynamics Q1 2027 Earnings Call: Complete Transcript

Earnings Scheduled For October 8, 2026

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session

AngioDynamics to Participate in Upcoming Investor Conferences

Full Transcript: AngioDynamics Q4 2026 Earnings Call

Earnings Scheduled For July 14, 2026

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

Earnings Scheduled For April 2, 2026

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference

AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

Dow Jumps Over 400 Points; US Services Activity Falls In December

US Stocks Mixed; Nasdaq Gains Over 50 Points

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

What to Expect from AngioDynamics's Earnings

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference